Hematopoietic stem cell transplantation (HSCT) for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP):...

Area of Science:

• Neurology
• Immunology
• Hematology

Background:

• Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves.
• Standard treatments like intravenous immunoglobulin and plasmapheresis are not always effective, leading to treatment dependency.
• Autologous hematopoietic stem cell transplantation (HSCT) is an emerging therapeutic option for refractory CIDP.

Purpose of the Study:

• To evaluate the efficacy and outcomes of autologous HSCT in patients with CIDP.
• To identify factors influencing treatment success in CIDP patients undergoing HSCT.
• To emphasize the importance of accurate diagnosis and disease staging for HSCT in CIDP.

Main Methods:

• Retrospective analysis of CIDP patients who underwent autologous HSCT.
• Assessment of treatment-free remission rates, clinical improvements, and electrophysiological parameters post-HSCT.
• Review of diagnostic criteria and disease progression in patients before and after HSCT.

Main Results:

• Approximately 80% of CIDP patients achieved 5-year treatment-free remission after HSCT.
• Significant improvements were observed in muscle strength, ambulation, quality of life, and nerve conduction studies.
• Patient selection based on accurate CIDP diagnosis and disease stage is critical for favorable outcomes.

Conclusions:

• Autologous HSCT is a highly effective treatment for eligible CIDP patients, offering long-term remission and functional recovery.
• Accurate pre-HSCT diagnosis and staging are paramount to maximize treatment success and avoid HSCT in non-CIDP neuropathies.
• Re-evaluation for alternative diagnoses is recommended for patients who do not respond to HSCT.